Dear Community Member, At Bayer, we are strongly committed to supporting the hemophilia A community. We know that maintaining access to hemophilia A treatment is extremely important, and to help those in need we have recently raised the upper limit in our Kogenate® FS, antihemophilic factor (recombinant) Co-pay Assistance Program.* Previously the Co-pay Assistance Program offered $6,000 in assistance. Eligible patients can now be covered up to $12,000 in co-pay assistance for their Kogenate® FS therapy. The amount of assistance available is calculated using a sliding scale based on income. More than one person in a household can be eligible for assistance, as long as they meet the program requirements. Enrollment is fast and simple. Here's what you have to do:             Call Bayer Factor Solutions: A Case Specialist will complete an application on the patient's behalf                 Provide financial documentation to Patient Services, Inc. (PSI), who administers the program, when requested                 Present the co-pay card—which will be mailed to the patient—to the pharmacy when ordering Kogenate® FS     Call 1-800-288-8374 between 8:30 am and 5:30 pm (ET) to connect with a Factor Solutions Case Specialist. Spanish-speaking Case Specialists are available.         *  People with private, commercial health insurance may receive Kogenate® FS co-pay or co-insurance assistance, based on eligibility requirements and income level. The program is on a first-come, first-served basis. Financial support is available for up to12 months. Eligible patients can re-enroll for additional 12-month courses. The program is not for patients receiving prescription reimbursement under any federal-, state-, or government-funded insurance programs, or where prohibited by law. All people who meet these criteria are encouraged to apply. Factor Solutions Co-pay Assistance Eligibility Criteria What is offered through the program? PSI will administer and determine eligibility for the program to help Kogenate® FS patients afford their co-pay/co-insurance expenses. Kogenate® FS patients are qualified to apply for the program* if: They have hemophilia A They meet specific financial criteria for enrollment (patients may be eligible for up to $12,000 in co-pay assistance) They currently have private health insurance Amount of assistance is income dependent: Patients who earn under 400% of the Federal Poverty Limit can receive up to $12,000 in assistance for factor payments Patients who earn over 400% of the Federal Poverty Limit and under 800% of the Federal Poverty Limit can receive up to $500 in assistance Who is not eligible for assistance? Patients on public health insurance are not eligible for assistance at this time. This includes but is not limited to patients insured through Medicare, Medicaid, TRICARE, DOD plans, pre-existing condition insurance plan (PCIP), and high-risk plans associated with a PCIP Patients enrolled in Bayer Assistance Programs Once approved for assistance: Funds administered by PSI can only be used towards a patient's co-pay/co-insurance expenses for Bayer's Kogenate® FS As a condition of payment, patients and pharmacies must comply with all contractual obligations made with third-party payers and insurance companies, and must provide notice of any benefits received and the value of this program to all payers as required by law, contract, or otherwise INDICATIONS   Kogenate® FS, antihemophilic factor (recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Kogenate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage. IMPORTANT SAFETY INFORMATION   Kogenate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins. The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to AHF. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections. For important risk and use information, please click here for full Prescribing Information.         Bayer, the Bayer Cross, and Kogenate are registered trademarks of Bayer. Bayer HealthCare, 67 Whippany Road, Whippany, NJ 07981-0915 © 2014 Bayer HealthCare Pharmaceuticals Inc. All rights reserved 2/14 KN56000814